Cho Jae Hoon
Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Konkuk University, Seoul, Republic of Korea.
J Rhinol. 2023 Mar;30(1):15-22. doi: 10.18787/jr.2022.00416. Epub 2023 Mar 30.
Although positive airway pressure (PAP) is known to be more effective than uvulopalatopharyngoplasty (UPPP) in the treatment of obstructive sleep apnea (OSA), PAP is a more expensive treatment in Korea. Therefore, it is necessary to compare the cost-effectiveness of these two treatments.
We assumed patients with moderate to severe OSA and divided them into three groups: those who used PAP (the PAP Treatment group), those who received UPPP (surgery group), and those who did not receive a diagnosis or treatment (No Treatment group). We compared their medical costs over 10 years. The incidence rate of common complications and accidents (coronary heart disease, heart failure, stroke, depression, diabetes, vehicle accident, and work-related accident) with or without treatment was adopted through a literature review. The average medical expenses for treating each complication and accident were also found by searching several databases.
The incidence of all complications was higher in the control group than in the PAP Treatment group or the surgery group. However, since the absolute incidence rate was not high in all groups and medical expenses in Korea are low, the expected treatment cost was not high (KRW 108,209 per year for the PAP Treatment group, KRW 141,228 for the surgery group, and KRW 178,369 for the No Treatment group). In contrast, the costs of a polysomnography examination, PAP rental, and mask purchase were relatively high. Based on these results, the 10-year medical expenses for the PAP Treatment group were KRW 10,246,948, and those for the surgery were only KRW 925,095.
Although PAP treatment reduces the incidence of complications in OSA patients, it is not as cost-effective as UPPP in Korea, where medical costs are low.
尽管已知气道正压通气(PAP)在治疗阻塞性睡眠呼吸暂停(OSA)方面比悬雍垂腭咽成形术(UPPP)更有效,但在韩国,PAP治疗费用更高。因此,有必要比较这两种治疗方法的成本效益。
我们假设患者为中度至重度OSA,并将他们分为三组:使用PAP的患者(PAP治疗组)、接受UPPP的患者(手术组)以及未接受诊断或治疗的患者(未治疗组)。我们比较了他们10年的医疗费用。通过文献综述采用了接受或未接受治疗的常见并发症和事故(冠心病、心力衰竭、中风、抑郁症、糖尿病、车祸和工伤事故)的发生率。通过搜索多个数据库也找到了治疗每种并发症和事故的平均医疗费用。
对照组中所有并发症的发生率均高于PAP治疗组或手术组。然而,由于所有组中的绝对发生率都不高且韩国的医疗费用较低,预期治疗成本并不高(PAP治疗组每年108,209韩元,手术组141,228韩元,未治疗组178,369韩元)。相比之下,多导睡眠图检查、PAP租赁和面罩购买的费用相对较高。基于这些结果,PAP治疗组10年的医疗费用为10,246,948韩元,而手术的费用仅为925,095韩元。
尽管PAP治疗可降低OSA患者并发症的发生率,但在韩国这种医疗成本较低的情况下,其成本效益不如UPPP。